AHA 2017: Canagliflozin Reduced Cardiovascular Death, Nonfatal MI, and Nonfatal Stroke in Patients With Type 2 Diabetes and Elevated Risk of CV Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.